These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 32006423)

  • 1. Fracture risks among patients with atrial fibrillation receiving different oral anticoagulants: a real-world nationwide cohort study.
    Huang HK; Liu PP; Hsu JY; Lin SM; Peng CC; Wang JH; Loh CH
    Eur Heart J; 2020 Mar; 41(10):1100-1108. PubMed ID: 32006423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of Osteoporosis in Patients With Atrial Fibrillation Using Non-Vitamin K Antagonist Oral Anticoagulants or Warfarin.
    Huang HK; Liu PP; Hsu JY; Lin SM; Peng CC; Wang JH; Yeh JI; Loh CH
    J Am Heart Assoc; 2020 Jan; 9(2):e013845. PubMed ID: 31918601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of developing diabetes in patients with atrial fibrillation taking non-vitamin K antagonist oral anticoagulants or warfarin: A nationwide cohort study.
    Huang HK; Liu PP; Lin SM; Hsu JY; Peng CC; Munir KM; Wu TY; Yeh JI; Loh CH; Tu YK
    Diabetes Obes Metab; 2021 Feb; 23(2):499-507. PubMed ID: 33140538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Stroke, Bleeding, and Mortality Risks in Older Medicare Patients Treated with Oral Anticoagulants for Nonvalvular Atrial Fibrillation.
    Graham DJ; Baro E; Zhang R; Liao J; Wernecke M; Reichman ME; Hu M; Illoh O; Wei Y; Goulding MR; Chillarige Y; Southworth MR; MaCurdy TE; Kelman JA
    Am J Med; 2019 May; 132(5):596-604.e11. PubMed ID: 30639551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation and valvular heart disease.
    Li HJ; Lin SY; Lin FJ; Hung CS; Wang CC
    Curr Med Res Opin; 2021 Apr; 37(4):535-542. PubMed ID: 33538623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 7. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation.
    Lee HF; Chan YH; Chang SH; Tu HT; Chen SW; Yeh YH; Wu LS; Kuo CF; Kuo CT; See LC
    J Am Heart Assoc; 2019 Mar; 8(5):e011112. PubMed ID: 30834802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
    Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
    Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing the Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants and Warfarin in Elderly Asian Patients With Atrial Fibrillation: A Nationwide Cohort Study.
    Chao TF; Chiang CE; Liao JN; Chen TJ; Lip GYH; Chen SA
    Chest; 2020 May; 157(5):1266-1277. PubMed ID: 31809694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non-vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage.
    Tsai CT; Liao JN; Chiang CE; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Chung FP; Chao TF; Lip GYH; Chen SA
    JAMA Netw Open; 2020 Jun; 3(6):e206424. PubMed ID: 32478848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of frailty on the effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a nationwide cohort study.
    Grymonprez M; Petrovic M; De Backer TL; Steurbaut S; Lahousse L
    Eur Heart J Qual Care Clin Outcomes; 2024 Jan; 10(1):55-65. PubMed ID: 36941126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of anticoagulant therapy with risk of dementia among patients with atrial fibrillation.
    Kim D; Yang PS; Jang E; Yu HT; Kim TH; Uhm JS; Kim JY; Sung JH; Pak HN; Lee MH; Lip GYH; Joung B
    Europace; 2021 Feb; 23(2):184-195. PubMed ID: 33063123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of oral anticoagulants in elderly patients with atrial fibrillation.
    Rutherford OW; Jonasson C; Ghanima W; Söderdahl F; Halvorsen S
    Heart; 2022 Mar; 108(5):345-352. PubMed ID: 33975877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The risk of acute kidney injury in Asians treated with apixaban, rivaroxaban, dabigatran, or warfarin for non-valvular atrial fibrillation: A nationwide cohort study in Taiwan.
    Chan YH; Yeh YH; Hsieh MY; Chang CY; Tu HT; Chang SH; See LC; Kuo CF; Kuo CT
    Int J Cardiol; 2018 Aug; 265():83-89. PubMed ID: 29885705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients.
    Lip GYH; Keshishian A; Li X; Hamilton M; Masseria C; Gupta K; Luo X; Mardekian J; Friend K; Nadkarni A; Pan X; Baser O; Deitelzweig S
    Stroke; 2018 Dec; 49(12):2933-2944. PubMed ID: 30571400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of heart failure in elderly patients with atrial fibrillation and diabetes taking different oral anticoagulants: a nationwide cohort study.
    Lin SM; Liu PP; Tu YK; Lai EC; Yeh JI; Hsu JY; Munir KM; Peng CC; Huang HK; Loh CH
    Cardiovasc Diabetol; 2023 Jan; 22(1):1. PubMed ID: 36609317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes in elderly atrial fibrillation patients at increased bleeding risk treated with very low dose vs. regular-dose non-vitamin K antagonist oral anticoagulants: a nationwide cohort study.
    Chan YH; Chao TF; Chen SW; Lee HF; Li PR; Yeh YH; Kuo CT; See LC; Lip GYH
    Eur Heart J Cardiovasc Pharmacother; 2023 Dec; 9(8):681-691. PubMed ID: 37580139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Real-world Experience of the Safety and Efficacy of Non-vitamin K Oral Anticoagulants Versus Warfarin in Patients with Non-valvular Atrial Fibrillation-A Single-centre Retrospective Cohort Study in Singapore.
    Tiew WJ; Wong VL; Tan VH; Tan YC; Lee EM
    Ann Acad Med Singap; 2020 Nov; 49(11):838-847. PubMed ID: 33381777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study.
    Staerk L; Gerds TA; Lip GYH; Ozenne B; Bonde AN; Lamberts M; Fosbøl EL; Torp-Pedersen C; Gislason GH; Olesen JB
    J Intern Med; 2018 Jan; 283(1):45-55. PubMed ID: 28861925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The association of non-vitamin K antagonist oral anticoagulants
    Yang N; Zhao Y; Bai Z; Chen H; Ning H; Zou M; Cheng G
    Acta Cardiol; 2023 May; 78(3):298-310. PubMed ID: 36063197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.